Harbor Branch Oceanographic Institute, Florida Atlantic University, 5600 US Highway 1 North, Fort Pierce, FL 34946, USA.
Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL 32826, USA.
Mar Drugs. 2021 Mar 25;19(4):179. doi: 10.3390/md19040179.
Novel drug leads for malaria therapy are urgently needed because of the widespread emergence of resistance to all available drugs. Screening of the Harbor Branch enriched fraction library against the chloroquine-resistant strain (Dd2) followed by bioassay-guided fractionation led to the identification of two potent antiplasmodials; a novel diterpene designated as bebrycin A () and the known C21 degraded terpene nitenin (). A SYBR Green I assay was used to establish a Dd2 EC of 1.08 ± 0.21 and 0.29 ± 0.02 µM for bebrycin A and nitenin, respectively. Further analysis was then performed to assess the stage specificity of the inhibitors antiplasmodial effects on the Dd2 intraerythrocytic life cycle. Exposure to bebrycin A was found to block parasite maturation at the schizont stage if added any time prior to late schizogony at 42 hours post invasion, (HPI). In contrast, early life cycle exposure to nitenin (prior to 18 HPI) was identified as crucial to parasite inhibition, suggesting nitenin may target the maturation of the parasite during the transition from ring to early trophozoite (6-18 HPI), a novel property among known antimalarials.
由于所有现有药物的耐药性广泛出现,迫切需要新型抗疟药物先导化合物。对 Harbor Branch 富化馏分库进行抗氯喹抗性株(Dd2)筛选,然后进行基于生物测定的馏分分离,鉴定出两种有效的抗疟药物;一种新型二萜化合物命名为 bebrycin A()和已知的 C21 降解萜类化合物 nitenin()。SYBR Green I 测定法确定 bebrycin A 和 nitenin 的 Dd2EC 分别为 1.08 ± 0.21 和 0.29 ± 0.02 µM。然后进行进一步分析,以评估抑制剂对 Dd2 红细胞内生活周期的阶段特异性抗疟作用。如果在 42 小时入侵后晚期裂殖体之前的任何时间添加 bebrycin A,就会发现它可阻止疟原虫成熟至裂殖体阶段。相比之下,早期生活周期中 nitenin 的暴露(在 18 HPI 之前)被确定为对寄生虫抑制至关重要,这表明 nitenin 可能靶向寄生虫在从环到早期滋养体(6-18 HPI)的过渡期间的成熟,这是已知抗疟药中的一种新特性。